Please Wait...
Please Wait...
Ceftriaxone is indicated in the treatment of
the following infections in adults and children including term neonates (from birth):
· Bacterial
Meningitis
· Community
acquired pneumonia
· Acute
otitis media
· Intra-abdominal
infections
· Urinary
tract infections
· Infections
of joint and bones
· Skin
and soft tissue infections
· Gonorrhoea,
Syphilis
· Bacterial
endocarditis
· For
treatment of acute exacerbations of chronic obstructive pulmonary disease in
adults
· For
treatment of disseminated Lyme borreliosis (early (stage II) and late (stage
III)) in
adults
and children including neonates from 15 days of age.
Pre-operative prophylaxis of surgical site infections
Ceftriaxone is a broad-spectrum antibiotic used to treat various bacterial infections in adults, children, and neonates. It is effective against conditions like bacterial meningitis, pneumonia, urinary tract infections, skin infections, bone and joint infections, and intra-abdominal infections.
It also treats sexually transmitted infections such as gonorrhoea and syphilis, and is used for surgical infection prevention and Lyme disease. The injection provides strong and targeted antibiotic action. Common side effects may include mild stomach upset, allergic reactions, or injection site irritation.
Each vial contains:
Sterile Ceftriaxone Sodium
USP
Eq. to Ceftriaxone anhydrous
………….. 1 g
Pack Contains:
Sterile Water for Injection USP (Vial of 10ml)
Intramuscular administration/ Intravenous administration
DOSAGE
As directed by the physician
• Pain,
Induration, Tenderness at the site of infection (1%) less frequently phlebitis
was seen
after IV doses.
• Rash, Pruritus, Fever, Chills
• Eosinophilia, Thrombocytosis, Leukopenia, Anaemeia, Neutropenia,
Lymphopenia,
Thrombocytopenia
• Diarrhoea, Nausea, vomiting, Diageusia
• Headache, dizziness
• Moniliasis/vaginitis
In renal failure no adjustment may be necessary but serum level should be monitored periodically and the dosage reduced if required. Dosage adjustment is similarly not essential in hepatic failure but in patients with hepatic and significant renal malfunction. Lavincef doses should not exceed 2 g/day without close serum monitoring. Rarely, alterations in prothrombin time have occurred and may require coadministration of vitamin K (10 mg weekly). Prolonged use may cause overgrowth of non-susceptible organism and cause hyper infection. Administer with caution to patients with history of G.I. diseases, especially, colitis
Combi-pack
containing 10 ml vial of Ceftriaxone for injection and 10 ml ampoule of sterile
water for injection USP along with pack insert.